BioSpace News Archive

Diabetes is common metabolic disorder that is found in 30 million people alone in the US.

The global drug delivery system market is poised for significant growth in the years ahead.

Radioactive isotopes have been a boon for several industries. They are a variation of a chemical substance with a different mass.

United Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO)

Miroculus, Inc. today announced that it will unveil its first commercial platform, the Miro Canvas, at the Advances in Genome Biology and Technology conference in Marco Island, FL.

GenapSys Inc., the company behind the world’s first highly accurate, affordable, and portable gene sequencer, today announced a new OEM partnership with Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA.

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that John A. Hohneker, M.D., president and chief executive officer of Anokion, will present a company overview at the Cowen 40th Annual Healthcare Conference

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia

Progressive Care Inc., a personalized healthcare services and technology company, announced that CEO, S. Parikh Mars, will be the keynote speaker at Cold Chain Global Forum West Coast in San Diego, CA on February 26-27, 2020.

Avanos Medical, Inc. (NYSE: AVNS) today announced that it would present at the following two investor conferences in March: